Can a virus be the ultimate weapon against cancer?

Health · Published 7 October 2026 Swipe more like this →

In short: Doctors have been observing cancer remission following viral infections for over a century. Today, oncolytic virus therapy is evolving from a curious observation into a precise medical tool, using viruses to selectively destroy tumors and train the immune system to hunt cancer cells throughout the body.

Oncolytic viruses (OVs) function through a dual mechanism. First, they exploit vulnerabilities in cancer cells—such as defective antiviral pathways—to selectively replicate and lyse the tumor. This direct destruction releases tumor-associated antigens, essentially alerting the immune system to the presence of the malignancy. Such mechanisms can shift a tumor's microenvironment from an immune-suppressive to an immune-permissive state, which may spark a systemic antitumor reaction. This process can also disrupt tumor angiogenesis and extracellular matrix remodeling. Consequently, these viruses help interfere with the progression and metastasis of the disease.

The field has transitioned through distinct generations of development. Early 20th-century research focused on wild-type viruses, but these often caused severe systemic infections or organ failure. The 1990s marked a turning point with genetic engineering, allowing for the creation of first-generation OVs that delete pathogenic genes to increase tumor selectivity. Second-generation viruses, such as the herpes simplex virus-based T-VEC, are engineered to express transgenes like GM-CSF to further amplify immune recruitment. Modern researchers are now investigating RNA-based platforms like measles virus for their rapid replication. Additionally, some viruses are being modified to act as carriers for specific transgene delivery.

While the field is rapidly expanding, significant hurdles remain. Clinical implementation is currently limited by challenges in viral dissemination dynamics, therapy resistance, and regulatory complexities. Even with these obstacles, the commercial sector is expanding; the global market reached $20.1 million in 2023 and should see a 26.9% compound annual growth rate until 2032. As of 2022, over 400 clinical trials were underway to evaluate OVs across various cancers, including glioblastoma and pancreatic cancer. Approved treatments currently include Talimogene laherparepvec for melanoma and Rigvir for skin cancer. Furthermore, new candidates like Replimune are undergoing regulatory review to expand these therapeutic options.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• Engineered viruses show promise as multi-pronged cancer treatments
• Could viruses be the secret weapon we need to defeat cancer?
• Can we fight a virus by using another virus against it?
• Why have billions in research failed to find a universal cure for cancer?
• Training the immune system to hunt cancer cells without harming healthy tissue
• A high-stakes German raid in the Arctic that achieved almost nothing
• The high-speed race to build India's electric mobility backbone
• The secret society of journalists using a mysterious phrase to prank editors
• How one smart card became the essential pulse of Hong Kong life
• Can community-based interventions break the cycle of childhood stunting in tribal regions?
• The invisible engine driving every Windows operation from hardware to memory
• How a Tokyo tennis tournament evolved through decades of shifting prestige

More in Future Frontier · More in Health · Latest · A–Z · All topics